EGFR inhibition in non-small cell lung cancer: current evidence and future directions

EGFR inhibition has emerged to be an important strategy in the treatment of non-small cell lung cancer (NSCLC). Small molecule tyrosine kinase inhibitors (TKIs) and mono-clonal antibodies (mAbs) to the EGFR have been tested in multiple large randomized phase III studies alone or combined with chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Alexander, Remick, Scot, Tse, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776244/
https://www.ncbi.nlm.nih.gov/pubmed/24252457
http://dx.doi.org/10.1186/2050-7771-1-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776244/
https://www.ncbi.nlm.nih.gov/pubmed/24252457
http://dx.doi.org/10.1186/2050-7771-1-2

Ejemplares similares